Predicting Factors of Interstitial Lung Disease in Dermatomyositis and Polymyositis
Authors/Creators
- 1. TB Chest, Associate Professor, Vedantaa Institute of Medical Sciences, Saswand, Dahanu (Palghar) Maharashtra
- 2. MD Dermatology, Associate Professor, Vedantaa Institute of Medical Sciences, Saswand, Dahanu (Palghar) Maharashtra
Description
The aim of this study was to define the predicting factors and evaluate the prognosis of interstitial lung disease in dermatomyositis/polymyositis. For the period 2018–2022, we retrospectively reviewed the clinical information and laboratory data of 56 patients who were diagnosed as definite and probable dermatomyositis and polymyositis. Interstitial lung disease is common (41.9%) in these patients. Dyspnoea and cough were the two most common initial presentations. Anti-Jo1 antibody was more common in those with interstitial lung disease. Univariate and multivariate analyses identified primary idiopathic dermatomyositis subtype, cough and dyspnoea at onset to be the three independent clinical predicting factors of interstitial lung disease. High serum lactate dehydrogenase level (>400 U/l) was inversely associated with development of interstitial lung disease (OR 0.088, p=0.031). Serum lactate dehydrogenase level and presence of anti- Jo1 antibody can serve as laboratory indicators of lung complications. Patients with malignancy and older age at onset (more than 60 years) had poorer prognosis for dermatomyositis/polymyositis (p=0.047 and p=0.035, respectively). Interstitial lung disease did not affect the survival of dermatomyositis/polymyositis patients.
Abstract (English)
The aim of this study was to define the predicting factors and evaluate the prognosis of interstitial lung disease in dermatomyositis/polymyositis. For the period 2018–2022, we retrospectively reviewed the clinical information and laboratory data of 56 patients who were diagnosed as definite and probable dermatomyositis and polymyositis. Interstitial lung disease is common (41.9%) in these patients. Dyspnoea and cough were the two most common initial presentations. Anti-Jo1 antibody was more common in those with interstitial lung disease. Univariate and multivariate analyses identified primary idiopathic dermatomyositis subtype, cough and dyspnoea at onset to be the three independent clinical predicting factors of interstitial lung disease. High serum lactate dehydrogenase level (>400 U/l) was inversely associated with development of interstitial lung disease (OR 0.088, p=0.031). Serum lactate dehydrogenase level and presence of anti- Jo1 antibody can serve as laboratory indicators of lung complications. Patients with malignancy and older age at onset (more than 60 years) had poorer prognosis for dermatomyositis/polymyositis (p=0.047 and p=0.035, respectively). Interstitial lung disease did not affect the survival of dermatomyositis/polymyositis patients.
Files
IJPCR,Vol15,Issue5,Article83.pdf
Files
(480.3 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:ec682b39f87b6c0b657d9c2dae3a595d
|
480.3 kB | Preview Download |
Additional details
Dates
- Accepted
-
2023-05-05
Software
- Repository URL
- https://impactfactor.org/PDF/IJPCR/15/IJPCR,Vol15,Issue5,Article83.pdf
- Development Status
- Active
References
- 1. Callen JP. Thevalue of malignant evaluation patients with dermatomyositis. J Am Acad Dermatol 1982; 6:253–259. 2. Miller FW. Polymyositis and dermatomyositis. In: Goldman L, Ausiello D, eds. Cecil textbook of medicine, 22nd edition. Philadelphia: Saunders, 2004;1680–1684. 3. MarieI, Harton PY, Hachulla E, Wallaert B, Michon Pasturel, Devulder B. Pulmonary Involvement In Polymyositis And dermatomyositis. J Rheumatol. 1998; 25:1336–1343. 4. Fathi M, Dastmalchi M, Rasmussen E, Lundberg IE, Tomling G. Interstitial lung disease, a common manifestation misdiagnosed polymyositis derma to myositis. Ann Rheum Dis. 2004; 63:297–301. 5. Marie I, Hachulla E, CherinP, Dominique S, Hatron PY, Hellot MF, et al. Interstitial Lung Disease In Polymyositis And derma to myositis. Arthritis Rheum. 2002; 47:614–622. 6. Lakhanpal S, Lei JT, Conn DL, Martin WJ II. Pulmonary disease in polymyositis /dermatomyositis: a clinicopathologic analysis of 65 autopsy cases. Ann Rheum Dis. 1987; 46:23–29. 7. Arsura EL, Greenberg AS. Adverse impact of interstitial pulmonary fibrosis on prognosis in polymyositis and dermatomyositis. Semin Arthritis Rheum. 1988; 18:29–37. 8. Takizawa H, Shiga J, MoroiY, Miyachi S, Nishiwaki M, MiwamotoT. Interstitial lung disease in dermatomyositis: clinicpathological study. J Rheumatol. 1987; 14:102–107. 9. Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med. 1975; 292: 344–347,403–407. 10. Ansell BM. Juvenile derma to myositis. Rheum Dis Clin North Am. 1991; 17:931–941. 11. Fathi M, Lundberg E. Interstitial lung disease in polymyositis and dermatomyositis. Curr Opin Rheumatol. 2005; 17: 701–706. 12. Miller FW. Myositis-specific autoantibodies: touchstones for understanding the inflammatory myopathies. JAMA. 1993; 270:1846– 1849. 13. Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, et al. Anew approach to the classification of idiopathic inflammatory myopathy: myositisspecific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore). 1991; 70:360– 374. 14. Yokoyama A, Kondo K, Nakajima M, Matsushima T, Takahashi T, Nishimura M, et al. Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis. Respiratory. 2006; 11:164–168. 15. Yokoyama A, Kohno N, Hamada H, Sakatani M, ueda E, Kondo K, et al. Circulating KL-6 predicts the outcome of rapidly progressive idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1998; 158:1680–1684. 16. Kim EA, Lee KS, Johkoh T, Kim TS, Suh GY, Kwon OJ, et al. Interstitial lung diseases associated with collagen vascular diseases: radiologic and histopathologic findings. Radio Graphics 2002; 22: S151–S165. 17. Fujisawa T, Suda T, Nakamura Y, Enomoto N, Ide K, Toyoshima M, et al. Differences in clinical features and prognosis of interstitial lung disease between polymyositis and derma to myositis. J Rheumatol. 2005; 32:58– 64. 18. Chen Y, Wu C, Shen J. Predicting factors of malignancy in derma to myositis and polymyositis: a casecontrol study. Br J Dermatol 2001; 144:825–831. 19. Mautner GH, Grossman ME, Silvers DN, Rabinowitz A, Mowad CM, Johnson BL Jr. Epidermal necrosis as a predictive sign of malignancy in adult derma to myositis. Cutis. 1998; 61:190–194. 20. Benbassat J, Gefel D, Larholt K. Prognostic factors in polymyositis/ dermatomyositis. Arthritis Rheum. 1985; 28: 249–255. 21. Maugars YM, Berthelot JM, Abbas AA, Mussini JM, Nguyen JM, Prost AM. Long term prognosis of 69 patients with dermatomyositis or polymyositis. Clin Exp Rheumatol. 1996; 14:263–274. 22. Callen JP. Collagen vascular disease. J Am Acad Dermatol. 2004; 51:427– 439. 23. Oddis CV. Current approach to the treatment of polymyositis and dermatomyositis. Curr Rheumatol. 2000; 12:492–497. 24. Callen JP. Dermatomyositis. Lancet. 2000; 355:53–57. 25. Briemberg HR, Amato AA. Dermatomyositis and poly- myositis. Curr Treat Opt Neurol. 2003; 5:349– 356. 26. Takada K, Nagasaka K, Miyasaka N. Polymyositis/ derma to myositis and interstitial lung disease: a new therapeutic approach with T-cellspecific immunosuppressants. Autoimmunity. 2005; 38:383–392. 27. Dheyab Z. S. Clinically Important Yersinia: Minireview. Journal of Medical Research and Health Sciences, 2022; 5(10): 2295–2306.